reports
Cellectar Biosciences Announces Strategic Supply Agreement with Ioneti...
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a multi-year supply agreement with Ionetix Corporation, a leading cyclotron technology inno...
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and...
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party (SAWP) Initiated Phase 1b Study of CLR 125 for TNBC Received Rare Pediatric Drug Designation for Iopofosine I 131 in Inoperable Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., ...
Cellectar Biosciences to Report Third Quarter Financial Results and Ho...
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2025, and provide a corporate update on November 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, November...
Cellectar Biosciences Receives Rare Pediatric Disease Designation from...
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival FLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today...
Cellectar Biosciences Presented Promising Preclinical Data in Poster P...
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that ...
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Milli...
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the company and several institutional investors to exercise certain existing warrants (the “Existing Warrants”) for gross proceeds to the company of approximately $5.8 million prior to deducting placement agent fees and estimated offering expe...
Cellectar Biosciences Announces European Medicines Agency (EMA) Confir...
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected in Early 2026 Potential 2027 European Approval and Commercial Launch of Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM FLORHAM PARK, N.J., O...
Cellectar Biosciences Presented Compelling Data in Oral Session and Pa...
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall Survival FLORHAM PARK, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the trea...
Cellectar and Evestia Clinical Announce Partnership to Support Auger-E...
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025 FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist ...
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Act...
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors FLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CLRB, “Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and , a leading radiopharmaceutical biotech company, today announced a supply agreement for Actinium-225 (Ac-225). The agreement will support the clinical...
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targete...
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention to Pursue an Accelerated Approval with the U.S. Food and Drug Administration for Iopofosine I 131 as a Treatment for WM Advancing Auger-Emitting Radiopharmaceutical Product Candidate into Phase 1b Clinical Trial for the Treatment of Tr...
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meet...
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer at Cellectar Biosciences, will participate in panel discussions and present at multiple medical meetings and industry conferences in September. Details are as follows: ADC and Novel Conjugates ...
Cellectar Biosciences to Present Data in Poster Presentation at the Am...
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28...
Cellectar Biosciences to Present Data in Oral Session and Panel Discus...
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Patients FLORHAM PARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the accep...
Cellectar Biosciences Reports Second Quarter 2025 Financial Results an...
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025 On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025 Company to Hold Webcast and Conference Ca...
Cellectar Biosciences to Report Second Quarter Financial Results and H...
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2025, and provide a corporate update on August 14, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursd...
- Jonathan Moreland
MERC MERCER INTERNATIONAL INC.
CDXS CODEXIS
PETS PETMED EXPRESS INC.
CLRB CELLECTAR BIOSCIENCES
NHF NEXPOINT CREDIT STRATEGIES FUN
CZWI CITIZENS COMMUNITY BANCORP
LOOP LOOP INDUSTRIES
CHMG CHEMUNG FINANCIAL CORP.
FVCB FVCBANKCORP
FGBI FIRST GUARANTY BANCSHARES
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CMTV COMMUNITY BANCORP INC. VT
DMAC DIAMEDICA THERAPEUTICS INC.
CRDF CARDIFF ONCOLOGY INC
IMRX IMMUNEERING CORP
NSPR INSPIREMD INC
BRCC BRC INC
LEXX LEXARIA BIOSCIENCE CORP
PMNT PERFECT MOMENT LTD.
DMA DESTRA MULTI ALTERNATIVE FUND
NYC NEW YORK CITY REIT
GF INC.
FGEN THE NEW GERMANY FUND
CCIF INC.
CVM FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
CEL-SCI CORPORATION
- Jonathan Moreland
SIGI SELECTIVE INSURANCE GROUP INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
RLI RLI CORP.
PRGS PROGRESS SOFTWARE CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
HELE HELEN OF TROY LIMITED
WELL WELLTOWER INC.
CTAS CINTAS CORPORATION
CIVB CIVISTA BANCSHARES
MEDP MEDPACE HOLDINGS INC.
DYN DYNEGY INC.
PETS PETMED EXPRESS INC.
PBT PERMIAN BASIN ROYALTY TRUST
LIND LINDBLAD EXPEDITIONS HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
CRSP CRISPR THERAPEUTICS AG
CRVL CORVEL CORP.
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
COGT COGINT
BWB INC.
PGC BRIDGEWATER BANCSHARES
LOOP PEAPACK-GLADSTONE FINANCIAL CORP.
CHMG LOOP INDUSTRIES
A2JHXF CHEMUNG FINANCIAL CORP.
FVCB CEVA LOGISTICS AG
FGBI FVCBANKCORP
REZI FIRST GUARANTY BANCSHARES
GRX RESIDEO TECHNOLOGIES
PCB INC.
FRHC THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CMTV PACIFIC CITY FINANCIAL CORP
KYMR FREEDOM HOLDING CORP
DMAC COMMUNITY BANCORP INC. VT
NSPR KYMERA THERAPEUTICS
BRCC DIAMEDICA THERAPEUTICS INC.
BPRN INSPIREMD INC
STRW BRC INC
PMNT BANK OF PRINCETON
NYC STRAWBERRY FIELDS REIT INC.
GF PERFECT MOMENT LTD.
LION NEW YORK CITY REIT
FGEN INC.
BMNR THE NEW GERMANY FUND
NEGG INC.
LIONSGATE STUDIOS CORP
FIBROGEN INC.
BITMINE IMMERSION TECHNOLOGIES INC.
NEWEGG COMMERCE INC.
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
HELE HELEN OF TROY LIMITED
WELL WELLTOWER INC.
CEVA CEVA INC.
CDTX CIDARA THERAPEUTICS
CIVB CIVISTA BANCSHARES
NXRT NEXPOINT RESIDENTIAL TRUST INC.
DYN DYNEGY INC.
GIII G-III APPAREL GROUP LTD.
PETS PETMED EXPRESS INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
CRSP CRISPR THERAPEUTICS AG
CRVL CORVEL CORP.
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
COGT COGINT
BWB INC.
DOMO BRIDGEWATER BANCSHARES
FGBI DOMO INCORPORATED
PVH FIRST GUARANTY BANCSHARES
GRX PHILLIPS-VAN HEUSEN CORPORATION
INLX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
FRHC INTELLINETICS
CMTV INC.
RZLT FREEDOM HOLDING CORP
KYMR COMMUNITY BANCORP INC. VT
BTBT REZOLUTE
TERN INC.
CTO KYMERA THERAPEUTICS
VERA BIT DIGITAL (N SHARES)
IMRX TERNS PHARMACEUTICALS
BRCC CONSOLIDATED-TOMOKA LAND CO
BPRN VERA THERAPEUTICS INC
PMNT IMMUNEERING CORP
NYC BRC INC
ACTU BANK OF PRINCETON
MBRX PERFECT MOMENT LTD.
LION NEW YORK CITY REIT
THAR INC.
FGEN ACTUATE THERAPEUTICS INC.
CCIF MOLECULIN BIOTECH INC.
BMNR LIONSGATE STUDIOS CORP
NEGG THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
BITMINE IMMERSION TECHNOLOGIES INC.
NEWEGG COMMERCE INC.
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
PSEC PROSPECT CAPITAL CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
WELL WELLTOWER INC.
CEVA CEVA INC.
CDTX CIDARA THERAPEUTICS
PZG PARAMOUNT GOLD NEVADA CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
CRVL CORVEL CORP.
SVRA SAVARA
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
RSSS RESEARCH SOLUTIONS
BWB BRIDGEWATER BANCSHARES
DOMO DOMO INCORPORATED
FGBI FIRST GUARANTY BANCSHARES
PVH PHILLIPS-VAN HEUSEN CORPORATION
AMPY AMPLIFY ENERGY
INLX INTELLINETICS
FRHC INC.
CMTV FREEDOM HOLDING CORP
RZLT COMMUNITY BANCORP INC. VT
KYMR REZOLUTE
WSC INC.
BTBT KYMERA THERAPEUTICS
TERN WILLSCOT MOBILE MINI HOLDINGS CORP
NUVB BIT DIGITAL (N SHARES)
CTO TERNS PHARMACEUTICALS
VERA NUVATION BIO INC (A)
IMRX CONSOLIDATED-TOMOKA LAND CO
XLO VERA THERAPEUTICS INC
SSBK IMMUNEERING CORP
PMNT XILIO THERAPEUTICS INC
NYC SOUTHERN STATES BANCSHARES INC
ACTU PERFECT MOMENT LTD.
SUNS NEW YORK CITY REIT
MBRX INC.
LION ACTUATE THERAPEUTICS INC.
HYMC SUNRISE REALTY TRUST
THAR MOLECULIN BIOTECH INC.
FGEN LIONSGATE STUDIOS CORP
CCIF HYCROFT MINING HOLDING CORPORATION
BTCS THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
TOUCHIT TECHNOLOGIES
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.